Day: September 2, 2020

170161-27-0, Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

a 1-[4-(bromomethyl)phenylmethyl]-4,8,11-tri-(t-butoxycarbonyl)-1,4,8,11-tetraazacyclotetradecane alpha,alpha’-Dibromo-p-xylene (36.0 g, 136 mmol) was stirred at 60 C. in acetonitrile (500 mL) until it dissolved. Potassium carbonate (3.5 g, 25.3 mmol) was added, followed by the dropwise addition of a solution of 1,4,8-tri-(t-butyloxycarbonyl)-1,4,8,11-tetraazacyclotetradecane (Boitrel, et. al., Tetrahedron Lett., 1995, 36, 4995) (6.0 g, 11.98 mmol) in acetonitrile (100 mL). The mixture was stirred for 6 hours, cooled and partially evaporated. The excess dibromoxylene was filtered off, the mother liquors evaporated under vacuum and chromatographed (silica gel, 50% dichloromethane/hexane to 2% methanol/dichloromethane) to afford the title compound as a foam (7.4 g, 90%). MS (ES+) m/e 683 and 685 [M+H]+

170161-27-0, The synthetic route of 170161-27-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SmithKline Beecham Corporation; US2002/107195; (2002); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.103505-54-0,[2,2′-Bipyridine]-6,6′(1H,1’H)-dione,as a common compound, the synthetic route is as follows.,103505-54-0

As shown in scheme 1-b, [Cp*IrCl2]2 (458.4 mg, 0.570 mmol) was reacted with 6,6?-dihydroxy-2,2?-bipyridine ligand (250.0 mg, 1.33 mmol) in methanol solvent (8 mL), a reaction was carried out at 60 C. for 3 hours, and filtration using a glass filter was then carried out to thus give cationic complex A? (yield 74%). Subsequently, cationic complex A? (100.0 mg, 0.170 mmol) was reacted with potassium t-butoxide (38.3 mg, 0.340 mmol) in water (5 mL) at room temperature for 30 minutes while stirring, and a solid thus precipitated was filtered to thus give complex 1 (yield 64%).1H NMR (400 MHz, CD3OD) delta 7.43 (t, J=8 Hz, 2H), 6.92 (d, J=8 Hz, 2H), 6.43 (d, J=8 Hz, 2H), 1.59 (s, 15H). 13C{1H} NMR (125.8 MHz, CD3OD) delta 170.9, 157.3, 139.9, 118.1, 106.9, 88.0, 9.83. Anal. Calcd for C20H23O3N2Ir: C, 45.18; H, 4.36; N, 5.27. Found: C, 45.47; H, 4.01; N, 5.62.

The synthetic route of 103505-54-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Kanto Kagaku Kabushiki Kaisha; Yamaguchi, Ryohei; Fujita, Ken-ichi; (26 pag.)US2016/297844; (2016); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

128143-89-5, 4′-Chloro-2,2′:6′,2”-terpyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

28 mg (<5 mol %) of zinc(II) chloride and 4.4 g (61.5 mmol) of pyrrolidine are added in succession to a mixture of 1.1 g (4.1 mmol) of 4-chloro-[2,2';6',2]terpyridine in 15 ml of 2-methyl-2-butanol. The mixture is heated at reflux for 20 hours, cooled and filtered. Pure 4'-pyrrolidin-1-yl-[2,2';6',2]terpyridine is obtained in the form of a white solid after recrystallisation from toluene. MS (EI, 70 eV): m/z=303 (15); 302 (90, [M+]); 273 (100); 233 (25). 1H-NMR (360 MHz, CDCl3): 1.9-2.0 (m, 4H); 3.39-3.49 (m, 4H); 7.18 (dd, 2H, J=6.7, 5.2 Hz); 7.51 (s, 2H); 7.66-7.76 (tm, 2H); 8.51 (d, 2H, J=7.7 Hz); 8.54-8.60 (m, 2H). 128143-89-5, As the paragraph descriping shows that 128143-89-5 is playing an increasingly important role.

Reference£º
Patent; Wieprecht, Torsten; Schlingloff, Gunther; Xia, Juntao; Heinz, Uwe; Schneider, Abert; Dubs, Marie-Josee; Bachmann, Frank; Hazekamp, Menno; Dannacher, Josef; US2006/19853; (2006); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

56-54-2, (S)-(6-methoxyquinolin-4-yl)((1S,2R,4S,5R)-5-vinylquinuclidin-2-yl)methanol is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,56-54-2

Example 6 (S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic Acid, Quinidine Salt (XXVIII) (rac)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid THF-solvate (XXVI) (555 g, 0.910 mol) was prepared at 20 C. in butyl acetate (2.22 l) and combined with (+)-quinidine (334.3 g; 1.03 mol). Heating was then done to 50 C. and stirring for 1 h at 50 C. After cooling to 5 C., filtering was done and the filter cake was stirred with butyl acetate (1.2 l), filtered again, and washed with butyl acetate (0.7 l). Drying was done at 40 C. in vacuum. Yield: 361 g (45% of theory) of a cream-colored solid. 1H-NMR (400 MHz, DMSO-d6): delta=1.58 (m, 2H), 1.79 (m, 1H), 2.04 (m, 1H), 2.07 (s, 3H), 2.33 (m, 1H), 2.77 (s, 3H), 2.79 (m, 1H), 2.90 (m, 2H), 3.21 (m, 1H), 3.33 (m, 2H), 3.51 (s, 3H), 3.90 (s, 3H), 5.11 (d, 1H), 5.14 (d, 1H), 5.53 (br. s, 1H), 6.09 (ddd, 1H), 6.72 (s, 1H), 7.75 (m, 2H), 7.82 (m, 1H), 7.92 (br. s, 1H), 8.11 (br. d, 1H), 8.27 (d, 1H), 8.46 (s, 1H), 12.75 (br. s, 1H).

56-54-2 (S)-(6-methoxyquinolin-4-yl)((1S,2R,4S,5R)-5-vinylquinuclidin-2-yl)methanol 637552, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Patent; pH Pharma, Ltd.; Schirmer, Heiko; Rubenbauer, Philipp; Keil, Birgit; Olenik, Britta; (29 pag.)US2018/72685; (2018); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

53344-72-2,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.53344-72-2,6,6′-Dichloro-2,2′-bipyridine,as a common compound, the synthetic route is as follows.

General procedure: Oven-dried Schlenk flask was evacuated and backfilled with argon three times. In the stream of argon heteroaryl dichloride (1 eq), K2CO3 (3 eq) were placed thereto. Secondary phosphine oxide (2.4 eq) was dissolved in DMF (15 ml/mmol) and the solution was added to the flask. The solution was bubbled with argon for 10 min and Pd(OAc)2 (0.02 eq) and dppf (0.04 eq) were added to the flask simultaneously. The resulting mixture was heated at 80oC for 7 h and then poured into fourfold excess of brine. The mixture was extracted with CH2Cl2 three times (40 ml/mmol each). Combined organic extracts were washed with brine to remove traces of DMF, dried over anhydrous Na2SO4 and then evaporated to dryness. The residue was purified by column chromatography on silica gel 40-60 using CH2Cl2-MeOH mixture as eluent.

As the paragraph descriping shows that 53344-72-2 is playing an increasingly important role.

Reference£º
Article; Zakirova, Gladis G.; Mladentsev, Dmitrii Yu.; Borisova, Nataliya E.; Tetrahedron Letters; vol. 58; 35; (2017); p. 3415 – 3417;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

137076-54-1, 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

(12) To a mixture of compound (Y11) (26 mg), tri-tert-butyl 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (16 mg), DMF (500 muL), and DIEA (21 muL), HATU (23 mg) was added, and the resulting mixture was stirred at room temperature for 5 minutes. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (chloroform/ethanol/ammonia water=7/3/0.5) to obtain compound (Y12) (25 mg). TLC Rf: 0.22 (chloroform/ethanol/ammonia water=7/3/0.5)

137076-54-1, As the paragraph descriping shows that 137076-54-1 is playing an increasingly important role.

Reference£º
Patent; FUJIFILM Corporation; FUJIFILM RI PHARMA CO., LTD.; FUKUNAGA, Hirofumi; DOZONO, Hiroyuki; HINO, Akihiro; OSHIKIRI, Shinobu; NAGANO, Akio; (99 pag.)US2016/199520; (2016); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

485-71-2, Cinchonidine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,485-71-2

Resolution of the enantiomers of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazole-3-carboxylic acid The resolution of the enantiomers of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazole-3-carboxylic acid was carried out via reaction with the following chiral bases: BrucineQuinine(-)-Cinchonidine(+)-CinchonineR-(+)-1-Phenylethylamine(1 R,2S)-(-)-Ephedrine hydrochloride(1S,2R)-(+)-Ephedrine hydrochloride. In each case the reactions were carried out with 0.5 and 1 equivalents of base in respect to 1 equivalent of the acid compound and by using the following solvents EthanolAcetoneAcetonitrilDioxaneEthylacetateChloroform. The results are summarized in the following tables. It may be understood that the afore mentioned crystallisation experiments that are not reflected in the following tables did not yield crystals of the respective salts under the given conditions. However, suitable conditions for crystallization of these salts can be determined by those skilled in the art via routine experiments. In the following tables Acid represents racemic 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazo)e-3-carboxylic acid R-Acid represents the respective derivative of (R)-5-( 4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazole-3-carboxylic acid S-Acid represents the respective derivative of (S)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazole-3-carboxylic acidProcesses for crystallisation: Process A: A solution of the chiral base was added on top of a solution of the racemic acid at room temperature.Process C: A solution of the racemic acid was added on top of a solution of the chiral base. The mixture was heated to reflux and solvent was added until dissolution was complete. The solution was left to crystallisation at r.t.Process D: The chiral base was directly added on top of a solution of the racemic acid at room temperature.Process E: The chiral base was directly added on top of a solution of the racemic acid at reflux temperature.Process F: The solution of the salt was evaporated to dryness. The residue was dissolved in a minimum amount of the solvent under reflux heating. The solution was left to crystallisation at r.t.Resolution with (-)-Cinchonidine [Show Image] Acid g (mmol) Eq. amine Proc. Solvent for crystallisation T CrystYield 1st Cryst. % % S-Acid % R-Acid0,4 g (1,09 mmol) 1 F 2ml dioxane r.t 31 94,4 5,60,4 g (1,09 mmol) 1 F 19ml Ethylacetate r.t 28,5 95,8 4,20,4 g (1,09 mmol) 1 F 20ml acetone r.t. 19,6 96,9 3,10,4 g (1,09 mmol) 1 F 24ml acetonitrile r.t 42 85,8 14,1

As the paragraph descriping shows that 485-71-2 is playing an increasingly important role.

Reference£º
Patent; Laboratorios del Dr. Esteve S.A.; EP1944293; (2008); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

General procedure: A solution of x,y-bis(bromomethylnaphthalene) (x,y = 2,7, 2,6 or 1,6) (2,7-bis(bromomethyl)naphthalene;126 mg, 400 mumol / 2,6-bis(bromomethyl)naphthalene; 72.0 mg, 100 mumol / 1,6-bis(bromomethyl)naphthalene; 31.4 mg, 100 mumol)S1 was added to a solution of tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (50.1 mg, 100 mumol), KI (16.6 mg, 100 mumol) and K2CO3(10.8 mg, 78.0 mumol) in CH3CN (3.50 mL) under N2 and stirred for 24 h at room temperature. The reactionmixture was concentrated under reduced pressure and extracted with EtOAc. The organic layer was washedwith water and brine, dried with MgSO4 and concentrated in vacuo to obtain the corresponding tri-N-Bocprotectedamine intermediates. A solution of the intermediates was added to bis(pyridin-2-ylmethyl)amine(Dpa) (12.0 mg, 60.0 mumol) and K2CO3 (8.30 mg, 60.0 mumol) in CH3CN (3.00 mL) under N2 and stirred at80 C for 24 h. The reaction mixture was concentrated under reduced pressure and extracted with EtOAc.The organic layer was washed with water and brine, dried with MgSO4 and concentrated in vacuo to obtainthe corresponding tri-N-Boc-protected amine intermediates. The intermediates were then dissolved inCHCl3 (2.50 mL) and treated with 95% aqueous TFA (2.50 mL) at 0 C for 6.0 h. The mixture was concentrated under reduced pressure and purified by preparative HPLC to obtain the desired compounds 1-3.

170161-27-0, As the paragraph descriping shows that 170161-27-0 is playing an increasingly important role.

Reference£º
Article; Sakyiamah, Maxwell M.; Kobayakawa, Takuya; Fujino, Masayuki; Konno, Makoto; Narumi, Tetsuo; Tanaka, Tomohiro; Nomura, Wataru; Yamamoto, Naoki; Murakami, Tsutomu; Tamamura, Hirokazu; Bioorganic and Medicinal Chemistry; vol. 27; 6; (2019); p. 1130 – 1138;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.7089-68-1,2-Chloro-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

7089-68-1, A mixture of 150 mL of toluene, 4.28 g (20 mmol) of 2-chloro-1,10-phenanthroline and 1.03 g (120 mmol) piperazine were boiled up to the disappearance of original 2-chloro-1,10-phenanthroline. Control over the reaction course was carried out by means of TLC (chloroform :ethyl acetate = 1 : 1). Toluene was distilled off and the residue was dissolved in chloroform and chromatographed on silica gel, eluents?chloroform?ethyl acetate (1 : 1) and chloroform?ethanol (10 : 1).Yield 3.33 g (63percent). 1 NMR spectrum (CDCl3), delta,ppm: 9.04 d.d (1, H9, J = 4.3, 1.6 Hz), 8.08 d.d (1,H7, J = 8.1, 1.6 Hz), 7.90 d (1, H4, J = 9.1 Hz), 7.55d (1, H5, J = 8.5 Hz), 7.45 d.d (1, H8, J = 8.1,4.3 Hz), 7.41 d (1, H6, J = 8.6 Hz), 7.02 d (1, H3,J = 9.1 Hz), 3.90 t (4, H15, J =5.0 Hz), 2.98 t (4,H16, J = 5.0 Hz). 13C NMR spectrum (CDCl3), deltaC,ppm: 156.60 (C2), 148.52 (C9), 144.33 (C13), 144.26(C14), 137.25 (C4), 135.25 (C7), 128.57 (C12), 125.52(C5), 121.64 (C11), 121.53 (C6), 121.36 (C8), 108.76(C3), 43.59 (C15), 43.05 (C16).

As the paragraph descriping shows that 7089-68-1 is playing an increasingly important role.

Reference£º
Article; Kokina; Ustimenko, Yu. P.; Rakhmanova; Sheludyakova; Agafontsev; Plyusnin; Tkachev; Larionov; Russian Journal of General Chemistry; vol. 89; 1; (2019); p. 87 – 95; Zh. Obshch. Khim.; vol. 89; 1; (2019); p. 100 – 109,10;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

39069-02-8, 2,9-Dibromo-1,10-phenanthroline is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Stille couplingThe rigid ligand 66 was obtained by Stille bis-coupling, by condensing two residues of tributylstannylpyridazine 39 with the 2,9-dibromo-1,10-phenanthroline 65b, with a yield of 91%, whereas its dichlorinated homolog 65a enables only a more modest yield of 62% to be obtained (Scheme 31).

39069-02-8, 39069-02-8 2,9-Dibromo-1,10-phenanthroline 15448099, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Patent; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.); US2010/298562; (2010); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI